Handelsbanken Fonder AB Sells 7,500 Shares of Krystal Biotech, Inc. $KRYS

Handelsbanken Fonder AB cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 10.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 66,800 shares of the company’s stock after selling 7,500 shares during the quarter. Handelsbanken Fonder AB’s holdings in Krystal Biotech were worth $9,182,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after buying an additional 365,304 shares during the period. Nuveen LLC acquired a new stake in shares of Krystal Biotech during the first quarter worth about $42,223,000. Braidwell LP grew its position in shares of Krystal Biotech by 99.9% in the 1st quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after purchasing an additional 200,244 shares during the period. T. Rowe Price Investment Management Inc. bought a new position in Krystal Biotech in the first quarter valued at approximately $33,455,000. Finally, 1832 Asset Management L.P. acquired a new position in shares of Krystal Biotech in the first quarter valued at approximately $24,521,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on KRYS shares. Chardan Capital upped their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Wednesday. Citigroup increased their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, HC Wainwright reissued a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Monday, September 15th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $212.02 on Monday. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $214.72. The company has a market capitalization of $6.15 billion, a P/E ratio of 31.79 and a beta of 0.65. The company has a 50-day simple moving average of $186.30 and a 200 day simple moving average of $156.89.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The firm had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).